• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mylan CEO to testify before House panel over EpiPen pricing

September 14, 2016 By drugdelivery

Mylan's EpiPen(Reuters) –Mylan (NSDQ:MYL) Chief Executive Officer Heather Bresch will appear at a Sept. 21 congressional hearing over price increases for its EpiPen emergency allergy treatment, the U.S. House of Representatives Oversight Committee said in a statement on Wednesday.

Mylan has been widely criticized, including by U.S. Democratic presidential candidate Hillary Clinton, for sharply raising the price of EpiPens, which are carried by people with life-threatening allergies.

Mylan, which acquired the product in 2007, recently raised the list price for a pair of EpiPen auto-injectors to $600. The price has been rising from a cost of about $100 in 2008.

Mylan spokeswoman Nina Devlin confirmed that Bresch will attend the hearing.

“Heather is very good at being able to give an answer without offering much information,” said Evercore ISI analyst Umer Raffat, adding that he will be watching for any other issues that might be raised by the Committee.

A probe into EpiPen pricing by a U.S. Senate subcommittee was announced on Sept. 7.

Bresch is the daughter of U.S. Senator Joe Manchin, a Democrat from West Virginia.

The House panel co-chairmen, Republican Representative Jason Chaffetz and Democratic Representative Elijah Cummings, noted there is “… justified outrage from families and schools across the country struggling to afford the high cost of EpiPens.”

The committee planned to look at how to spur competition in the EpiPen market and speed approval by the Food and Drug Administration (FDA) of generic alternatives, according to the statement.

In response to the furor, Mylan last month said it would sell its own generic version of EpiPen for $300.

Teva Pharmaceutical Industries, which for years has been working on developing a generic alternative to EpiPen, said last week that it hopes to gain U.S. approval by late 2017 or early 20018.

EpiPen, which has annual sales of about $1 billion, delivers a potentially life-saving dose of epinephrine by injection into the thigh to counter dangerous allergic reactions, including to peanuts and bee stings. Mylan owns 94% of the market for such auto-injected devices.

The committee said it also planned to call as a witness Dr Doug Throckmorton, the FDA’s deputy director at the Center for Drug Evaluation and Research.

Filed Under: Drug-Device Combinations, Legal News, Wall Street Beat Tagged With: Mylan

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS